XENETIC BIOSCIENCES (UK) LIMITED

Get an alert when XENETIC BIOSCIENCES (UK) LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-06-26 (in 1mo)

Last made up 2025-06-12

Watchouts

None on the register

Cash

—

Latest balance sheet

Net assets

£7M

-31% vs 2023

Employees

—

Average over period

Profit before tax

-£3M

-15,536% vs 2023

Name history

Renamed 6 times since incorporation

XENETIC BIOSCIENCES (UK) LIMITED 2014-06-24 → present
XENETIC BIOSCIENCES (UK) PLC 2014-06-24 → 2014-06-24
XENETIC BIOSCIENCES PLC 2011-09-05 → 2014-06-24
LIPOXEN PLC 2006-01-16 → 2011-09-05
GREENCHIP INVESTMENTS PLC 1999-07-28 → 2006-01-16
INFANTCARE PLC 1996-09-04 → 1999-07-28
THOMPSON TURNBURY PLC 1996-06-12 → 1996-09-04

Net assets

2-year trend · vs Industrials median

XENETIC BIOSCIENCES (UK) LIMITED·Industrials median · n=6236

Accounts

2-year trend · latest reflected 2024-12-31

Metric	2023-12-31	2024-12-31
Turnover	—	—
Operating profit	£20,001	-£3,087,346
Profit before tax	£20,001	-£3,087,346
Net profit	£20,001	-£3,087,346
Cash	—	—
Total assets less current liabilities	£9,950,072	£6,862,726
Net assets	£9,950,072	£6,862,726
Equity	£9,950,072	£6,862,726
Average employees	—	—
Wages	—	—

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio	2023-12-31	2024-12-31
Return on capital employed	0.2%	-45.0%
Gearing (liabilities / total assets)	0.2%	0.2%
Current ratio	0.11x	0.09x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis: IFRS
Reporting scope: Standalone (parent only)
Auditor: F. W. Smith, Riches & Co.
Audit opinion: Unqualified (clean)
Going concern: Affirmed
“As a wholly owned-subsidiary of its US-listed parent company, Xenetic Biosciences, Inc (XBIO), the Company ultimately depends upon the Group for funding. Consequently, the directors have received a letter of comfort from XBIO confirming XBIO's intention to provide such level of financial support to the Company for a period of at least 12 months from the date of this Report such that the Company will be able to meet its obligations as they fall due.”

Group structure

XENETIC BIOSCIENCES (UK) LIMITED · parent
1. Lipoxen Technologies Limited 100% · England and Wales · research into drug delivery systems
2. SymbioTec GmbH 100% · Germany · early stage clinical trials
3. Xenetic Bioscience Incorporated 100% · United States of America · fund its operations

Significant events

“Notwithstanding that the Company's UK subsidiary, Lipoxen Technologies Limited, is currently profitable and cash-generative, since its inception, the business of the Group has incurred, and continues to incur, significant losses from operations.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

3 active · 28 resigned

Name	Role	Appointed	Born	Nationality
HILL, Colin	Secretary	2016-10-07	—	—
HILL, Colin William	Director	2001-11-08	Jun 1945	British
PARSLOW, James	Director	2018-02-16	Feb 1965	American

Show 28 resigned officers

Name	Role	Appointed	Resigned
KEITH, Philippa Anne	Secretary	1996-09-12	2000-10-20
CARGIL MANAGEMENT SERVICES LIMITED	Corporate Secretary	2000-10-20	2016-10-07
CARGIL MANAGEMENT SERVICES LIMITED	Corporate Nominee Secretary	1996-06-12	1996-09-12
BENTLEY, Alan Geoffrey	Director	1996-09-12	2001-11-23
BURNE, Ian Howard	Director	1996-09-12	2002-01-08
BURNE, Malcolm Alec	Director	1996-09-12	2006-01-16
CANNON BROOKES, Charles	Director	2002-01-08	2004-04-13
CHONG, Giap Wang	Director	2005-08-01	2007-06-11
DASTOOR, Firdaus Jal	Director	2007-04-11	2014-05-01
DOWNIE, Robert Hunter	Director	2002-01-08	2003-11-26
FOY, Kaare Glenne	Director	1996-09-12	2000-02-10
GENKIN, Dmitry Dmitrievich	Director	2006-01-16	2014-05-01
GREGORIADIS, Gregory	Director	2006-01-16	2014-05-01
ISAEV, Artur Alexandrovich	Director	2012-04-27	2014-05-01
KNYAZEV, Roman Sergeevich	Director	2012-01-27	2014-05-01
MAGUIRE, Michael Scott	Director	2006-01-16	2018-10-31
NIKOLAEV, Igor Anatolevich	Director	2008-10-03	2012-04-27
PAGE, Andrew	Director	2000-03-27	2001-06-10
RICHARDS, Brian Mansel, Sir	Director	2006-01-16	2014-05-01
SIMONDS, Gavin Napier	Director	2000-02-10	2001-06-15
WALLIS, Ian Hedley	Director	2000-04-03	2001-06-15
ZHURAVSKAYA, Tatiana, Dr	Director	2006-01-16	2008-10-06
CARGIL MANAGEMENT SERVICES LIMITED	Corporate Director	1996-06-12	1996-06-12
CARGIL MANAGEMENT SERVICES LIMITED	Corporate Director	1996-06-12	1996-09-12
DRIMIN LIMITED	Corporate Director	1996-06-12	1996-06-12
LEA YEAT LIMITED	Corporate Director	1996-06-12	1996-09-12
LEA YEAT LIMITED	Corporate Nominee Director	1996-06-12	1996-06-12
VENCAP LIMITED	Corporate Director	1996-06-12	1996-06-12

Ownership

Persons with significant control

Name	Kind	Nature of control	Notified	Status
Xenetic Biosciences, Inc.	Corporate entity	Shares 75–100%, Voting 75–100%, Appoints directors	2016-04-06	Active

Filing timeline

Last 20 of 301 total filings

Date	Type	Category	Description
2025-10-01	AA	accounts	Accounts with accounts type full
2025-06-23	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2025-06-20	CH01	officers	Change person director company with change date	PDF
2024-09-27	AA	accounts	Accounts with accounts type full
2024-07-04	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2023-10-06	AA	accounts	Accounts with accounts type full
2023-06-19	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2023-01-05	AA	accounts	Accounts with accounts type full
2022-08-05	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2022-01-07	AA	accounts	Accounts with accounts type full
2021-07-28	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2021-01-13	AA	accounts	Accounts with accounts type full
2020-06-30	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2020-06-30	PSC05	persons-with-significant-control	Change to a person with significant control	PDF
2019-10-08	AA	accounts	Accounts with accounts type full
2019-09-26	TM01	officers	Termination director company with name termination date	PDF
2019-07-12	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2018-10-04	AA	accounts	Accounts with accounts type full
2018-07-24	CS01	confirmation-statement	Confirmation statement with no updates	PDF
2018-02-19	AP01	officers	Appoint person director company with name date	PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings: 3
Capital events: 0
Officers appointed: 0
Officers resigned: 0

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Turnover

—

Not reported
Cash

—

Not reported
Net assets

-31%

£9,950,072 £6,862,726
Employees

—

Not reported
Operating profit

-15,536%

£20,001 -£3,087,346
Profit before tax

-15,536%

£20,001 -£3,087,346

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page